Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsPatrick Moss has spoken on 4 earnings calls across 1 company, most recently for Sarepta Therapeutics, Inc. on November 5, 2026. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sarepta Therapeutics, Inc. includes Douglas Ingram (CEO and Board Member), Michael Severino, M.D. (CEO and Board Member), M. Kathleen Behrens (Chairman) and 7 others.
“Today, I will review our third quarter commercial performance, the work we are doing to support treatment decisions for Elevitus, and the continued strength of our broader Duchenne business.”
“Today, I'll summarize our performance of the first quarter for our on-market therapies, provide an update on execution of our 2026 initiatives, and close with how that translates into performance for second quarter and the balance of the year.”
“As pre-announced in January, net product revenue for 2025 totaled $1.86 billion, consisting of $966 million from our PMO franchise and $899 million for 11S. For the fourth quarter, net product revenues for the PMOs totaled $259 million, which is relatively stable compared to the fourth quarter of 2024.”
“My comments today will focus on three areas, a review of our Q3 performance, my thoughts on the Essence results, and our expectations for the trajectory of a Levitus.”
Source not stated
Biotechnology · Healthcare
